The FGF14 GAA repeat expansion in Greek patients with late‐onset cerebellar ataxia and an overview of the SCA27B phenotype across populations

Chrisoula Kartanou,Alexandros Mitrousias,David Pellerin,Zoi Kontogeorgiou,Pablo Iruzubieta,Marie‐Josée Dicaire,Matt C. Danzi,Chrysoula Koniari,Konstantinos Athanassopoulos,Marios Panas,Leonidas Stefanis,Stephan Zuchner,Bernard Brais,Henry Houlden,Georgia Karadima,Georgios Koutsis

DOI: https://doi.org/10.1111/cge.14482

2024-01-16

Clinical Genetics

Abstract:FGF14 GAA repeat expansions were recently associated with SCA27B. We screened 160 Greek patients with late‐onset cerebellar ataxia for SCA27B. We identified FGF14 repeat expansions in 12% of index cases. SCA27B is the commonest known genetic cause of late‐onset ataxia in Greece. We recommend prioritizing testing for FGF14 expansions in late‐onset ataxias. A pathogenic GAA repeat expansion in the first intron of the fibroblast growth factor 14 gene (FGF14) has been recently identified as the cause of spinocerebellar ataxia 27B (SCA27B). We herein screened 160 Greek index cases with late‐onset cerebellar ataxia (LOCA) for FGF14 repeat expansions using a combination of long‐range PCR and bidirectional repeat‐primed PCRs. We identified 19 index cases (12%) carrying a pathogenic FGF14 GAA expansion, a diagnostic yield higher than that of previously screened repeat‐expansion ataxias in Greek LOCA patients. The age at onset of SCA27B patients was 60.5 ± 12.3 years (range, 34–80). Episodic onset (37%), downbeat nystagmus (32%) and vertigo (26%) were significantly more frequent in FGF14 expansion‐positive cases compared to expansion‐negative cases. Beyond typical cerebellar signs, SCA27B patients often displayed hyperreflexia (47%) and reduced vibration sense in the lower extremities (42%). The frequency and phenotypic profile of SCA27B in Greek patients was similar to most other previously studied populations. We conclude that FGF14 GAA repeat expansions are the commonest known genetic cause of LOCA in the Greek population and recommend prioritizing testing for FGF14 expansions in the diagnostic algorithm of patients with LOCA.

genetics & heredity